MA Yan, CHENG Qianji, LU Yao, NING Jinling, GE Long. Applications and Challenges of Adaptive Platform Trial[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1157-1164. DOI: 10.12290/xhyxzz.2023-0424
Citation: MA Yan, CHENG Qianji, LU Yao, NING Jinling, GE Long. Applications and Challenges of Adaptive Platform Trial[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1157-1164. DOI: 10.12290/xhyxzz.2023-0424

Applications and Challenges of Adaptive Platform Trial

Funds: 

China Academy of Chinese Medical Sciences Innovation Fund CI2021A05502

More Information
  • Corresponding author:

    GE Long, E-mail: gelong2009@163.com

  • Received Date: September 06, 2023
  • Accepted Date: December 12, 2023
  • Available Online: January 26, 2024
  • Publish Date: January 25, 2024
  • Issue Publish Date: September 29, 2024
  • Adaptive design, with advantages such as dynamically adjusting trial plans, reducing resource waste, and improving trial efficiency, has broken through the competitive situation of new drug development and gradually met the needs of clinical research. In recent years, the use of adaptive design in platform trials as an innovative research model has added impetus to new drug development. This article outlines the research progress, contents and characteristics, common design types, statistical analysis, and case interpretation of adaptive design, and introduces the concept, types, and applications of adaptive platform trials, with the hope of providing scientific reference for further exploration of clinical trials and new drug development.

  • [1]
    杜艾桦. 药物临床试验适应性设计的科学性与伦理性问题[J]. 药物流行病学杂志, 2017, 26(12): 837-840.

    Du A H. Scientificity and ethicality of adaptive designs in drug clinical trials[J]. Chin J Pharmacoepidemiol, 2017, 26(12): 837-840.
    [2]
    王雨宁, 徐畅, 邓可, 等. 适应性设计在临床试验中的应用[J]. 中国循证医学杂志, 2020, 20(4): 487-491.

    Wang Y N, Xu C, Deng K, et al. Application of adaptive design in clinical trials[J]. Chin J Evid-Based Med, 2020, 20(4): 487-491.
    [3]
    杨凯璇, 周齐, 姜英玉, 等. 适应性设计随机对照临床试验[J]. 中国卒中杂志, 2022, 17(10): 1152-1158.

    Yang K X, Zhou Q, Jiang Y Y, et al. Adaptive design randomized controlled clinical trials[J]. Chin J Stroke, 2022, 17(10): 1152-1158.
    [4]
    Randy W. Deputy commissioner for medical and scientific affairs[EB/OL ]. (2006-07-10)[2023-11-26]. https://forums.lungevity.org/topic/21815-deputy-commissioner-for-medical-and-scientific-affairs/.
    [5]
    European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design[EB/OL ]. (2007-10-01)[2023-09-01]. https://www.ema.europa.eu/en/methodological-issues-confirmatory-clinical-trials-planned-adaptive-design-scientific-guideline.
    [6]
    Collignon O, Koenig F, Koch A, et al. Adaptive designs in clinical trials: from scientific advice to marketing authorisa-tion to the European Medicine Agency[J]. Trials, 2018, 19(1): 642. DOI: 10.1186/s13063-018-3012-x
    [7]
    Food and Drug Administration. Guidance for industry: adaptive design clinical trials for drugs and biologics[EB/OL]. (2010-02)[2023-09-01]. https://people.duke.edu/~ghturner/N492-Regulations%20and%20Guidelines/FDAdraftGuidance-AdaptiveStudiesUCM201790.pdf.
    [8]
    Committee on Rules. Rules committee print 114-67: text of house amendment to the senate amendment to H.R. 34, tsunami warning, education, and research act of 2015[EB/OL]. (2016-11-25)[2023-11-26]. https://docs.house.gov/billsthisweek/20161128/CPRT-114-HPRT-RU00-SAHR34.pdf.
    [9]
    U.S. Food and Drug Administration. Adaptive design clinical trials for drugs and biologics guidance for industry[EB/OL]. (2019-11-29)[2023-11-26]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry.
    [10]
    国家药品监督管理局药品审评中心. 药物临床试验适应性设计指导原则(试行)[EB/OL]. (2021-01-29)[2023-11-26]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=4409e51a403a911757af6caf3ecef129.

    National Medical Products Administration Drug Evaluation Center. Guidelines for adaptive design of drug clinical trials (trial)[EB/OL ]. (2021-01-29)[2023-11-26]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=4409e51a403a911757af6caf3ecef129.
    [11]
    衡明莉, 王北琪, 王骏. 对美国FDA适应性设计指导原则的介绍[J]. 中国临床药理学杂志, 2019, 35(12): 1316-1320.

    Heng M L, Wang B Q, Wang J. Introduction to the guidance for industry on adaptive designs for clinical trials of drugs and biologics issued by FDA[J]. Chin J Clin Pharmacol, 2019, 35(12): 1316-1320.
    [12]
    Wasson J M S, Dimairo M, Biggs K, et al. Practical guidance for planning resources required to support publicly-funded adaptive clinical trials[J]. BMC Med, 2022, 20(1): 254. DOI: 10.1186/s12916-022-02445-7
    [13]
    Burnett T, Mozgunov P, Pallmann P, et al. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs[J]. BMC Med, 2020, 18(1): 352. DOI: 10.1186/s12916-020-01808-2
    [14]
    Pallmann P, Bedding A W, Choodari-Oskooei B, et al. Adaptive designs in clinical trials: why use them, and how to run and report them[J]. BMC Med, 2018, 16(1): 29. DOI: 10.1186/s12916-018-1017-7
    [15]
    Jones R L, Ravi V, Brohl A S, et al. Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial[J]. JAMA Oncol, 2022, 8(5): 740-747. DOI: 10.1001/jamaoncol.2021.3547
    [16]
    Perkins G D, Quinn T, Deakin C D, et al. Pre-hospital assessment of the role of adrenaline: measuring the effective-ness of drug administration in cardiac arrest (PARAMEDIC-2): Trial protocol[J]. Resuscitation, 2016, 108: 75-81. DOI: 10.1016/j.resuscitation.2016.08.029
    [17]
    Perkins G D, Ji C, Deakin C D, et al. A randomized trial of epinephrine in out-of-hospital cardiac arrest[J]. N Engl J Med, 2018, 379(8): 711-721. DOI: 10.1056/NEJMoa1806842
    [18]
    Kapur J, Elm J, Chamberlain J M, et al. Randomized trial of three anticonvulsant medications for status epilepticus[J]. N Engl J Med, 2019, 381(22): 2103-2113. DOI: 10.1056/NEJMoa1905795
    [19]
    Suchting R, Green C E, De Dios C, et al. Citalopram for treatment of cocaine use disorder: a Bayesian drop-the-loser randomized clinical trial[J]. Drug Alcohol Depend, 2021, 228: 109054. DOI: 10.1016/j.drugalcdep.2021.109054
    [20]
    Filozof C, Chow S C, Dimick-Santos L, et al. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic[J]. Hepatol Commun, 2017, 1(7): 577-585. DOI: 10.1002/hep4.1079
    [21]
    Dawson S N, Chiu Y D, Klein A A, et al. Effect of high-flow nasal therapy on patient-centred outcomes in patients at high risk of postoperative pulmonary complications after cardiac surgery: a statistical analysis plan for NOTACS, a multicentre adaptive randomised controlled trial[J]. Trials, 2022, 23(1): 699. DOI: 10.1186/s13063-022-06607-z
    [22]
    Sevransky J E, Rothman R E, Hager D N, et al. Effect of vitamin C, thiamine, and hydrocortisone on ventilator- and vasopressor-free days in patients with sepsis: the VICTAS randomized clinical trial[J]. JAMA, 2021, 325(8): 742-750. DOI: 10.1001/jama.2020.24505
    [23]
    Giovagnoli A. The Bayesian design of adaptive clinical trials[J]. Int J Environ Res Public Health, 2021, 18(2): 530. DOI: 10.3390/ijerph18020530
    [24]
    Lai T L, Lavori P W, Shih M C. Adaptive trial designs[J]. Annu Rev Pharmacol Toxicol, 2012, 52: 101-110. DOI: 10.1146/annurev-pharmtox-010611-134504
    [25]
    Grayling M J, Wheeler G M. A review of available software for adaptive clinical trial design[J]. Clin Trials, 2020, 17(3): 323-331. DOI: 10.1177/1740774520906398
    [26]
    Swanson C J, Zhang Y, Dhadda S, et al. Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody[J]. Alzheimers Res Ther, 2022, 14(1): 70. DOI: 10.1186/s13195-022-00995-9
    [27]
    Hager D N, Hooper M H, Bernard G R, et al. The vitamin C, thiamine and steroids in sepsis (VICTAS) protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial[J]. Trials, 2019, 20(1): 197. DOI: 10.1186/s13063-019-3254-2
    [28]
    Sudhop T, Brun N C, Riedel C, et al. Master protocols in clinical trials: a universal Swiss Army knife?[J]. Lancet Oncol, 2019, 20(6): e336-e342. DOI: 10.1016/S1470-2045(19)30271-2
    [29]
    Hirakawa A, Asano J, Sato H, et al. Master protocol trials in oncology: review and new trial designs[J]. Contemp Clin Trials Commun, 2018, 12: 1-8. DOI: 10.1016/j.conctc.2018.08.009
    [30]
    The Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations[J]. Nat Rev Drug Discov, 2019, 18(10): 797-807. DOI: 10.1038/s41573-019-0034-3
    [31]
    金秋百, 张颖, 姜枫, 等. 反应适应性随机的实施要点及其在中医药临床研究中的应用前景[J]. 中医杂志, 2021, 62(17): 1478-1483.

    Jin Q B, Zhang Y, Jiang F, et al. The key elements of response adaptive randomization and its application in clinical researches of traditional Chinese medicine[J]. J Tradit Chin Med, 2021, 62(17): 1478-1483.
    [32]
    Berry S M, Connor J T, Lewis R J. The platform trial: an efficient strategy for evaluating multiple treatments[J]. JAMA, 2015, 313(16): 1619-1620. DOI: 10.1001/jama.2015.2316
    [33]
    Hey S P, Kimmelman J. Are outcome-adaptive allocation trials ethical?[J]. Clin Trials, 2015, 12(2): 102-106. DOI: 10.1177/1740774514563583
    [34]
    Parmar M K, Sydes M R, Cafferty F H, et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols[J]. Clin Trials, 2017, 14(5): 451-461. DOI: 10.1177/1740774517725697
    [35]
    Riddell C A, Zhao Y S, Petkau J. An adaptive clinical trials procedure for a sensitive subgroup examined in the multiple sclerosis context[J]. Stat Methods Med Res, 2016, 25(4): 1330-1345. DOI: 10.1177/0962280213480576
    [36]
    Wang G Q, Kennedy R E, Cutter G R, et al. Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment[J]. Alzheimers Dement (N Y), 2015, 1(1): 63-71. DOI: 10.1016/j.trci.2015.03.002
    [37]
    Meurer W J, Barsan W G. Spinal cord injury neuroprotection and the promise of flexible adaptive clinical trials[J]. World Neurosurg, 2014, 82(3/4): e541-e546.
    [38]
    Rugo H S, Olopade O I, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer[J]. N Engl J Med, 2016, 375(1): 23-34. DOI: 10.1056/NEJMoa1513749
    [39]
    James N D, Sydes M R, Clarke N W, et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial[J]. BJU Int, 2009, 103(4): 464-469. DOI: 10.1111/j.1464-410X.2008.08034.x
    [40]
    Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics[J]. Lancet Infect Dis, 2020, 20(9): e238-e244. DOI: 10.1016/S1473-3099(20)30484-9
    [41]
    Khubchandani J, Jordan T R, Yang Y T. Ebola, Zika, Corona…What is next for our world?[J]. Int J Environ Res Public Health, 2020, 17(9): 3171. DOI: 10.3390/ijerph17093171
    [42]
    Ellenberg S S. Clinical trials in the time of a pandemic[J]. Clin Trials, 2020, 17(5): 467-471. DOI: 10.1177/1740774520939871
    [43]
    Mulangu S, Dodd L E, Davey R T, Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics[J]. N Engl J Med, 2019, 381(24): 2293-2303. DOI: 10.1056/NEJMoa1910993
    [44]
    The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19[J]. N Engl J Med, 2021, 384(8): 693-704. DOI: 10.1056/NEJMoa2021436
    [45]
    Beigel J H, Tomashek K M, Dodd L E, et al. Remdesivir for the treatment of COVID-19-final report[J]. N Engl J Med, 2020, 383(19): 1813-1826. DOI: 10.1056/NEJMoa2007764
    [46]
    Noor N M, Pett S L, Esmail H, et al. Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings[J]. F1000Res, 2020, 9: 1109. DOI: 10.12688/f1000research.26253.1
    [47]
    Morgan CC, Huyck S, Jenkins M, et al. Adaptive design: results of 2012 survey on perception and use[J]. Ther Innov Regul Sci, 2014, 48(4): 473-481. DOI: 10.1177/2168479014522468
    [48]
    Bothwell L E, Avorn J, Khan N F, et al. Adaptive design clinical trials: a review of the literature and ClinicalTrials. gov[J]. BMJ Open, 2018, 8(2): e018320. DOI: 10.1136/bmjopen-2017-018320
    [49]
    赵超. 临床适应性设计与药物评价的考虑[J]. 中国临床药理学与治疗学, 2008, 13(1): 1-5. DOI: 10.3969/j.issn.1009-2501.2008.01.002

    Zhao C. General considerations on adaptive designs for clinical trail and drug evaluation[J]. Chin J Clin Pharmacol Ther, 2008, 13(1): 1-5. DOI: 10.3969/j.issn.1009-2501.2008.01.002
    [50]
    钱真真, 周莎, 于亚南, 等. 适应性随机化及其在临床试验中的应用操作要点[J]. 中国循证医学杂志, 2022, 22(8): 971-977.

    Qian Z Z, Zhou S, Yu Y N, et al. Adaptive randomization and its application in clinical trials[J]. Chin J Evid-Based Med, 2022, 22(8): 971-977.
    [51]
    范扬. 贝叶斯响应适应性随机化及其交互式Web应用实现[D]. 南京: 东南大学, 2020.

    Fan Y. On Bayesian response adaptive randomisation and its Web application implementation[D]. Nanjing: Southeast University, 2020.
    [52]
    Wright K, Ali J, Davies A, et al. Ethical priorities for international collaborative adaptive platform trials for public health emergencies[J]. BMJ Glob Health, 2023, 8(7): e012930. DOI: 10.1136/bmjgh-2023-012930
  • Related Articles

    [1]ZHANG Xueqin, ZHAO Yun, LIU Jie, GE Long, XING Ying, REN Simeng, WANG Yifei, ZHANG Wenzheng, ZHANG Di, WANG Shihua, SUN Yao, WU Min, FENG Lin, WEN Tiancai. Status of Clinical Practice Guideline Information Platforms[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 462-471. DOI: 10.12290/xhyxzz.2024-0496
    [2]LI Jianfeng, ZHANG Jingyi, LI Likang, LIU Yingxin, LI Guowei. Approach to Handling Missing Data in Clinical Trials[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1165-1172. DOI: 10.12290/xhyxzz.2023-0415
    [3]REN Yiming, LI Rui, TANG Si, JI Guanghe, QIN Zelin, ZHAO Leying, TONG Jiaxi, CHEN Yuxuan, GAO Jiaqi, YU Mingkun, RONG Hongguo, XIA Ruyu, FEI Yutong. Public's Knowledge and Experiences Towards Pediatric Clinical Trials: Methodological Characteristics Analysis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1076-1083. DOI: 10.12290/xhyxzz.2022-0620
    [4]BAI Xiaoyin, YANG Hong. Interpretation of Guidance for the Design and Implementation of Drug Clinical Studies: Based on E8 (R1): General Considerations for Clinical Trials[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 81-85. DOI: 10.12290/xhyxzz.2022-0611
    [5]XIE Jing, WANG Huanling. Patient-centric Clinical Trials: A New Paradigm for Drug Development[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 849-853. DOI: 10.12290/xhyxzz.2021-0056
    [6]HUANG Ping, FENG Bian-ying, MU Di, ZHOU Hao, YAO Zu-de, MAN Qiu-hong. Characteristics and Development of Platform Construction of Clinical Biobank in China[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 754-757. DOI: 10.3969/j.issn.1674-9081.2020.06.021
    [7]Yi-lin CHEN, Wei WEI, Xiu-hong LI, Xuan ZHANG, Tao HUANG, Ping ZHANG, Yun ZHANG. Comparisons of the Efficiency of Different Hospital-level Platform-based Sub-Biobanks in General Hospital[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 213-217. DOI: 10.3969/j.issn.1674-9081.20190074
    [8]Li-fan ZHANG, Xiao-qing LIU. Study Design and Clinical Practice of Diagnostic Accucary Test[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 96-101. DOI: 10.3969/j.issn.1674-9081.20190276
    [9]Jing LI, Huan SUN, Yong-hong LI. Common Misconceptions in Randomized Controlled Trials[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 166-171. DOI: 10.3969/j.issn.1674-9081.2019.02.016
    [10]Zhi-kai LIU, Xia LIU, Fu-quan ZHANG. Establishment of High-precision Irradiation Platform for Scientific Research and Measurement of Radiation Field[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(6): 421-425. DOI: 10.3969/j.issn.1674-9081.2016.06.004
  • Cited by

    Periodical cited type(3)

    1. 荆舒,戴振威,苏小游,李峥. 群医学理念在护理实践中的应用及启示. 中华护理杂志. 2025(04): 493-499 .
    2. 张祎冰,黄鹏. BOPPPS教学模式结合雨课堂在眼科临床见习中的应用. 医学研究杂志. 2024(09): 188-191 .
    3. 董樑,汪天翔,薛蔚,丁强. “4+4”临床医学培养模式中开展医工交叉的思考. 上海医学. 2024(08): 466-469 .

    Other cited types(0)

Catalog

    Article Metrics

    Article views (362) PDF downloads (50) Cited by(3)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close